|
|
|
|
|
|
|
SIZE:
|
|
|
|
GENERIC NAME:
|
|
|
|
MANUFACTURER:
|
|
|
|
UNIT:
|
|
|
|
ADMINISTRATION ROUTE:
|
|
|
|
FDA PREGNANCY GROUP:
|
|
B
|
|
INDICATIONS:
|
|
|
|
SIDE EFFECTS:
|
|
rhinitis |
|
Bleeding in eye |
|
redness in eye |
|
fibrosis |
|
Dry eye |
|
irritation, ocular |
|
Asthenia |
|
headache |
|
insomnia |
|
miosis |
|
mydriasis |
|
|
ABSOLUTE
CONTRAINDICATIONS :
|
|
|
|
RELATIVE
CONTRAINDICATIONS : |
|
>> Allergic reaction, such as anaphylaxis, bronchospasm, angioedema, allergic rhinitis, or urticaria, to aspirin or other systemic NSAIDs |
|
Epithelial herpes simplex keratitis, active |
|
Epithelial herpes simplex keratitis |
|
Hemophiliading problems |
|
Prolonged bleeding time |
|
>> Sensitivity to the ophthalmic NSAID considered for use |
|
Soft contact lenses, use of |
|
|
ADULT DOSE:
|
|
Miosis inhibitor, in ophthalmic surgery-Topical, to the conjunctiva, 1 drop every thirty minutes, beginning two hours prior to surgery, for a total of 4 drops.
[Anti-inflammatory, nonsteroidal, ophthalmic]-Treatment of inflammation following ophthalmic surgery or laser trabeculoplasty: Topical, to the conjunctiva, 1 drop every four hours for one to three weeks. |
|
MAXIMUM ADULT DOSE:
|
|
|
|
PEDIATRIC DOSE:
|
|
Safety and efficacy have not been established.
|
|
MAXIMUM PEDIATRIC
DOSE:
|
|
|
|
ELDERLY DOSE:
|
|
|
|
|
|
|
|